---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-013726"
form_type: "8-K"
ticker: "BMY"
cik: "0000014272"
company_name: "BRISTOL MYERS SQUIBB CO"
filed_at: "2024-03-18T23:59:59+00:00"
generated_at: "2026-06-04T14:55:54.148131+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Bristol-Myers Squibb completes $330/share acquisition of Karuna Therapeutics, adds schizophrenia drug KarXT

## Summary
- Each Karuna share converted into $330 cash; deal closed March 18, 2024.
- Lead asset KarXT (xanomeline-trospium) has PDUFA date Sept 26, 2024 for schizophrenia.
- Transaction expected to be dilutive ~$0.30 to non-GAAP EPS in 2024 from financing costs.
- One-time ~$12B Acquired IPR&D charge impacts Q1 2024 GAAP/non-GAAP EPS by ~$5.93.
- BMS to update financial outlook when reporting Q1 2024 results on April 25.

## SEC filing metadata
- accession: 0001140361-24-013726
- form_type: 8-K
- ticker: BMY
- cik: 0000014272
- company_name: BRISTOL MYERS SQUIBB CO
- filed_at: 2024-03-18T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/14272/000114036124013726/0001140361-24-013726-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/14272/000114036124013726/ef20024275_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-013726
- JSON: https://secwatch.observer/filing/0001140361-24-013726.json
- Plain text: https://secwatch.observer/filing/0001140361-24-013726.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.